<DOC>
	<DOCNO>NCT02882217</DOCNO>
	<brief_summary>The study focus evaluation safety tolerability XC8 . The design study involve sequential dosing cohort ( group volunteer ) , take increase dos product receive conclusion recommendation continuation study Dose Escalation Committee .</brief_summary>
	<brief_title>Study Assess Pharmacokinetics , Safety , Tolerability XC-8</brief_title>
	<detailed_description />
	<mesh_term>Histamine</mesh_term>
	<mesh_term>Histamine phosphate</mesh_term>
	<criteria>1 . Men woman age 18 50 year ; 2 . Generally good health ; 3 . Body mass index 19 30 kg/mÂ² &gt; 50 kg body weight ; 4 . Female subject postmenopausal ( menstrual period minimum 1 year ) , surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) , practice highly effective method birth control , i.e . resulting failure rate le 1 % per year use consistently correctly ( e.g . implant , injectables , combine oral contraceptive , intrauterine device , sexual abstinence , vasectomized partner ) . The birth control method must apply least 1 cycle 3 month administration study medication . 5 . Male subject female partner childbearing potential agree use medically acceptable method contraception ( e.g . condom , sexual abstinence , vasectomy ) study , 3 month last intake study medication . 6 . Subjects willing able ( opinion investigator ) understand comply procedure evaluation study . 7 . Subjects must willing legally able give write informed consent . 1 . Hepatic renal disease ; disease , may influence clinical trial result may lead health worsen trial ( accord investigator 's opinion ) ; 2 . Clinically significant laboratory abnormality ; 3 . Use medication , include prophylaxis , within 1 month screening ( include herbal preparation nutritional supplement ) ; 4 . Positive test human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) , hepatitis B virus HBV Screening ; 5 . Irregular sleep ( e.g . night work , sleep disturbance , insomnia , return another time zone , etc . ) ; 6 . History current evidence alcohol drug abuse ; alcohol drug intake within 4 day Screening ; 7 . History current evidence allergic reaction ( include reaction medication food ) ; 8 . History current evidence symptomatic rhinitis within 2 year Screening ( allergic rhinitis , nonallergic rhinitis , hay fever , exclude shortterm viral infection cold influenza ) ; 9 . Blood plasma donation , surgery ( hospital ) within 12 week Screening ; 10 . Lactating pregnant female ; positive pregnancy test first administration investigational medicinal product breastfeeding ; 11 . Current previous ( within 3 month enrollment ) treatment another investigational drug and/or medical device participation another clinical study ; 12 . Previous enrollment clinical study ; 13 . Inability understand follow protocol instruction ; 14 . Smoking within 3 month screen throughout study ; 15 . Lactose intolerance ; 16 . History allergic reaction XC8 inactive ingredient trial medication ; 17 . Employees sponsor subject employee relative investigator ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Double-blind</keyword>
	<keyword>Randomized</keyword>
	<keyword>Dose-escalating</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Phase I</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>Bronchial asthma</keyword>
	<keyword>Histamine glutarimide</keyword>
	<keyword>EURRUS</keyword>
</DOC>